Outlook Therapeutics (OTLK) AI Stock Analysis

• Market Cap: $35.05M
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: 86.28%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 83,067,190
• 10 Day Avg. Volume: 990,777
• 30 Day Avg. Volume: 1,543,346
• PEG Ratio: 0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 26.09
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 6.65K
• Enterprise Value/Revenue: 1.13M
• Enterprise Value/Gross Profit: -192.68K
• Enterprise Value/Ebitda: -3.85K
• 1Y Price Target: $3.83
• Price Target Upside: 811.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.77
• Revenue Forecast (FY): $21.14M

• Rating: 39 Underperform
• Price Target: $0.39 ▼(-7.86% Downside)
• Action: Downgraded Date: 02/19/26
• Date: Action: Downgraded 02/19/26

The score is weighed down primarily by very weak financial performance (large losses, negative equity, and heavy cash burn). Technicals also remain bearish with price below all major moving averages and negative MACD. Negative corporate events (Nasdaq bid-price noncompliance and an FDA CRL) add further risk, while valuation provides limited support given the negative P/E and no dividend.

Positive Factors

Exclusive Switzerland distribution partnership

An exclusive Swiss distribution deal delegates regulatory and commercial execution to a local partner while Outlook retains manufacturing and IP. This reduces upfront commercialization burden, accelerates market access in Europe, and creates a durable revenue channel and local presence despite U.S. delays.

Pivotal Phase 3 efficacy evidence (NORSE TWO)

A Phase 3 trial meeting primary and key secondary endpoints provides a strong scientific foundation for the program, supporting prescriber confidence and label claims. This durable clinical evidence underpins long-term commercial potential and regulatory dialogues even if additional confirmatory data are requested.

Authorized/establishing international foothold for Lytenava

On-label authorization in international markets creates a sustainable commercial pathway independent of U.S. approval, offering a differentiated, quality-controlled alternative to off-label bevacizumab. This supports long-term market penetration, reference use, and regional revenue diversification.

Negative Factors

Negative shareholders' equity / weak balance sheet

Accumulated negative equity reflects sustained losses and a depleted capital base, reducing financial flexibility. Over the medium term this elevates financing and covenant risk, limits strategic options like M&A or heavy commercialization investment, and increases likelihood of dilutive capital raises.

Severe, persistent cash burn

Consistent negative OCF and FCF with large 2025 outflows means operations cannot self-fund development or commercialization. Dependence on external funding is structurally limiting: it raises dilution risk, could delay launches if capital is scarce, and constrains long-term execution even with promising assets.

FDA Complete Response Letter requiring more confirmatory evidence

A CRL that demands more confirmatory efficacy evidence materially delays U.S. approval and market entry. This increases development cost and regulatory uncertainty, potentially prolonging dependence on non-U.S. revenues and partners, and weakening long-term U.S. commercial prospects in the core retina market.

Outlook Therapeutics Business Overview & Revenue Model

Company Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

How the Company Makes Money

Outlook Therapeutics makes money through the development and commercialization of its ophthalmic products. The company's revenue model is primarily centered around the successful approval and market launch of its lead product, ONS-5010, which is anticipated to generate sales revenue from its use in treating retinal diseases. The company may also engage in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product development capabilities and expand its market reach. Revenue streams are largely dependent on achieving regulatory approval and subsequent sales of its lead therapeutic, as well as potential licensing agreements or partnerships that can provide additional funding or revenue sharing opportunities.

Outlook Therapeutics Financial Statement Overview

Summary

Financials screen extremely weak: sharp TTM revenue decline (-85.46%), deeply negative margins, large recurring net losses (~$62M in 2025), negative shareholders’ equity, and severe ongoing operating/free-cash-flow burn indicating continued reliance on external funding.

Income Statement

Profitability is very weak. TTM (Trailing-Twelve-Months) shows a sharp revenue decline (-85.46%) and deeply negative gross profit and margins, indicating the business is not yet scaling commercially. Annual results also reflect persistent heavy losses (net loss of ~$62M in 2025 and ~$59–75M in prior years), and operating losses remain large relative to the revenue base, keeping earnings quality and visibility low.

Balance Sheet

The balance sheet is strained primarily due to negative shareholders’ equity (2025 annual and TTM), which signals accumulated losses and a thin capital cushion. Debt is meaningful and the negative equity makes leverage ratios difficult to interpret in a traditional way, but the setup still implies elevated financing risk. Earlier periods (2021–2024) show smaller scale balances with equity flipping from positive (2021–2022) to negative (2023–2024), reinforcing deterioration over time.

Cash Flow

Cash burn is severe and persistent. Operating cash flow and free cash flow are negative across all periods, with extremely large outflows reported in 2025 annual and TTM (Trailing-Twelve-Months). Cash generation does not currently support the income statement losses, and the company likely remains dependent on external funding to sustain operations and progress its pipeline.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	205.53K	1.41M	0.00	0.00	0.00	0.00
Gross Profit	-1.21M	657.21K	-113.86K	-44.19K	-204.69K	-262.14K
EBITDA	-60.47M	-63.58M	-72.09M	-57.38M	-64.36M	-51.51M
Net Income	-102.86M	-62.42M	-75.37M	-58.98M	-66.05M	-53.16M
Balance Sheet
Total Assets	18.24T	18.58T	28.82M	32.30M	28.53M	22.81M
Cash, Cash Equivalents and Short-Term Investments	8.68M	8.08T	14.93M	23.39M	17.40M	14.48M
Total Debt	233.11B	247.70B	29.74M	35.56M	10.96M	11.90M
Total Liabilities	56.79T	50.77T	101.90M	46.74M	19.79M	18.20M
Stockholders Equity	-38.55T	-32.19T	-73.08M	-14.44M	8.74M	4.61M
Cash Flow
Free Cash Flow	-14.94T	-51.83T	-68.79M	-42.97M	-56.67M	-54.25M
Operating Cash Flow	-14.94T	-51.83T	-68.79M	-42.97M	-56.67M	-54.25M
Investing Cash Flow	-3.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	15.53T	44.98T	60.33M	48.97M	59.59M	56.19M

Outlook Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLK, the sentiment is Negative. The current price of 0.42 is below the 20-day moving average (MA) of 0.43, below the 50-day MA of 0.81, and below the 200-day MA of 1.45, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 37.49 is Neutral, neither overbought nor oversold. The STOCH value of 32.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLK.

Outlook Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ORMP	62 Neutral	$132.94M	3.33	24.38%	―	―	814.20%
WHWK	56 Neutral	$152.70M	23.86	-13.82%	―	-42.62%	―
ADAG	53 Neutral	$139.51M	-4.59	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CELU	44 Neutral	$34.61M	-0.36	―	―	-15.81%	-113.06%
ATRA	43 Neutral	$39.08M	2.47	―	―	51.27%	―
OTLK	39 Underperform	$35.05M	-0.39	―	―	―	86.28%

Outlook Therapeutics Corporate Events

Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance

On February 18, 2026, Outlook Therapeutics received notice from Nasdaq that its common stock had closed below the required $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s continued listing standards. The notification does not immediately affect the stock’s listing, but the company has until August 17, 2026, to lift its closing bid price to at least $1.00 for ten consecutive business days or risk potential delisting, prompting management to monitor the share price and evaluate options such as a reverse stock split and possible appeal procedures if needed.

If Outlook Therapeutics fails to regain compliance by the August deadline and does not qualify for or succeed during an additional 180-day grace period, its stock could be delisted from the Nasdaq Capital Market, which may reduce liquidity and complicate capital-raising efforts. The situation underscores the company’s precarious market positioning and highlights the importance for shareholders of the firm’s forthcoming strategic decisions to address the low share price and maintain its Nasdaq listing.

The most recent analyst rating on (OTLK) stock is a Hold with a $0.41 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.

Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA

On February 11, 2026, Outlook Therapeutics announced it had requested a Type A meeting with the U.S. Food and Drug Administration to address a Complete Response Letter dated December 30, 2025, relating to its resubmitted biologics license application for ONS-5010/LYTENAVA for wet age-related macular degeneration. The letter cited a single deficiency, a purported lack of substantial evidence of effectiveness and a need for additional confirmatory data, a conclusion the company disputes based on prior FDA interactions and the totality of its clinical package.

Outlook Therapeutics emphasized that its BLA is backed by the Phase 3 NORSE TWO trial, which met primary and key secondary visual acuity endpoints at 12 months, and by NORSE EIGHT and other mechanistic, pharmacodynamic and natural history data that it says collectively satisfy the FDA’s substantial evidence standard. While NORSE EIGHT did not meet its primary endpoint at eight weeks, the company highlighted consistent vision gains through 12 weeks, a favorable safety profile comparable to existing anti-VEGF therapies, and argued that an FDA-approved, domestically manufactured bevacizumab for wet AMD could offer a standardized, high-quality alternative to current off-label use, making the outcome of these regulatory discussions significant for patients, prescribers and the U.S. retina market.

The most recent analyst rating on (OTLK) stock is a Sell with a $0.38 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.

FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA

On December 31, 2025, Outlook Therapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter to its resubmitted biologics license application for ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration, stating it could not approve the application in its current form and again calling for additional confirmatory evidence of efficacy without specifying what form that evidence should take. The setback delays potential U.S. approval despite the company’s reliance on data from its NORSE clinical trial program, including the successful NORSE TWO pivotal study and the NORSE EIGHT non-inferiority trial, and shifts strategic emphasis toward exploring alternative regulatory pathways in the U.S. while expanding commercialization and partnership efforts in Europe and other regions, where LYTENAVA is already authorized and beginning to establish a foothold as a differentiated, on-label bevacizumab option for wet AMD patients.

The most recent analyst rating on (OTLK) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.